Ryvu Therapeutics Signs A Grant Agreement For The Development Of Targeted Immuno-oncology Therapy
Ryvu Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, has signed a grant agreement with the National Centre for Research and Development for the development of targeted immuno-oncology therapy.
This grant provides Ryvu with almost USD 5.6 million of non-dilutive financing to discover, develop and select a clinical candidate targeting cancers which had been considered in the past as largely undruggable using rational approaches. Total net value of the project amounts to over USD 8.9 million and the anticipated project duration is until December 2023.
The aim of the project is development of a novel drug candidate, characterized in Phase I clinical study. The selected candidate should overcome the limitations of current immunotherapies, allowing effective and safe treatment options for patients with aggressive, refractory tumors. As a result of the conducted research, a small molecule immunomodulator of the patient's response against own cancer cells, serving as a strictly personalized therapy, will be identified.
The project is already in progress and the analysis of publicly available and commercial databases has confirmed that currently most advanced, compounds developed by Ryvu in this project, have the potential to become first-in-class medicines.
"Immuno-oncology has undeniably revolutionized the approach to cancer treatment. Immunotherapies offer a new chance to create an effective therapy for patients with aggressive, treatment-resistant cancers. With the financial support of the National Centre for Research and Development we can continue our research in the immune-oncology area at a full speed," commented Krzysztof Brzozka, PhD, Chief Scientific Officer and Executive VP at Ryvu Therapeutics.